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Summary
Background: Oral anticoagulant therapy with warfarin is essential for the optimal
prophylaxis of thrombosis and embolism in many vascular disorders whose preva-
lence is high among elderly patients. Elderly Caucasians show increased sensitivity
to oral anticoagulants. Although the Japanese are more sensitive to warfarin ther-
apy than Caucasians, the relationship between age and warfarin dosage in the
Japanese has not been investigated in detail. Here, we investigated this relationship
in Japanese patients.
Methods: The subjects comprised 102 outpatients (28—87 years) who showed a sta-
ble anticoagulant effect (prothrombin time expressed in terms of the international
normalized ratio [PT-INR] between 1.6 and 2.6) following long-term warfarin ther-
apy at the Department of Cardiovascular Medicine, National Hospital Organization
Hakodate Hospital. The relationship between age, PT-INR, and daily warfarin dose
was retrospectively investigated.
Results: The mean values of the characteristics of all the patients were as
follows: age, 70.7 (±10.5) years; daily dose of warfarin, 2.68 (±0.95)mg;
PT-INR, 1.99 (±0.24). The PT-INR was not correlated with increasing age.
The daily dosage of warfarin and the dosage adjusted according to the
PT-INR (dose/PT-INR), wherein the lower values indicate a higher sensitiv-
ity to warfarin therapy, were signiﬁcantly inversely correlated with age. In
the high PT-INR (PT-INR > 2.1) group, no signiﬁcant difference was observed
between the older and younger patients with regard to any characteristics.
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Conversely, in the low PT-INR (1.6≤PT-INR≤ 2.1) group, the dose/PT-INR was signif-
icantly reduced in the older patients (≥65 years); however, no signiﬁcant difference
was observed in the PT-INR value.
Conclusions: Both age and the controlled PT-INR value are factors responsible for the
increasing sensitivity to warfarin in Japanese patients under optimal anticoagulant
therapy. Since elderly Japanese patients with low PT-INR values are especially sensi-
tive to warfarin, greater caution should be exercised while determining the dosage
schedule in such patients.
e of Cardiology. Published by Elsevier Ireland Ltd. All rights© 2009 Japanese Colleg
reserved.
Introduction
Oral anticoagulant therapy with warfarin is essen-
tial for the optimal management of many vascular
disorders highly prevalent among elderly patients.
An increased sensitivity to oral anticoagulants has
been observed among elderly Caucasians [1—8],
which means that elderly patients require less
dosage of warfarin than younger patients for opti-
mal anticoagulant therapy. It has been proved
that as compared to Caucasians, the Japanese
have a higher incidence of bleeding at compara-
ble prothrombin times expressed in terms of the
international normalized ratio (PT-INR). Thus, the
Japanese are more sensitive to warfarin therapy
than Caucasians [9]. Therefore, the ‘‘Guidelines
for management of anticoagulant and antiplatelet
therapy in cardiovascular disease’’ in Japan [10]
recommend that the therapeutic range for warfarin
in the Japanese be lower than that in Caucasians.
Although the Japanese are observed to be highly
sensitive to warfarin therapy, the relationship
between the age of the patient and the dosage of
warfarin has not been investigated in detail.
In this study, we investigated the relationship
between age, daily dose of warfarin, and the daily
dose of warfarin adjusted for PT-INR (dose/PT-INR),
wherein the lower values indicate higher sensitivity
to warfarin therapy in each patient. Our results sug-
gest that both aging and controlled PT-INR values
are factors that can increase sensitivity to warfarin
in Japanese patients on optimal anticoagulant ther-
apy.
Methods
SubjectsThe subjects comprised 102 patients (aged 28—87
years) in whom a stable anticoagulant effect
(1.6≤PT-INR≤ 2.6) had been achieved under long-term warfarin therapy on an outpatient basis at the
Department of Cardiovascular Medicine, National
Hospital Organization (NHO) Hakodate Hospital.
Oral anticoagulation therapy was administered
once daily (morning or evening). The clinical char-
acters of the subjects were as follows.
The patients who take bucolome, a uricosuric
agent, were already excluded from the present
study, since in Japan, bucolome is usually pre-
scribed to increase sensitivity to warfarin therapy
by exploiting the warfarin—bucolome drug interac-
tion [11]. With regard to the frequency with which
typical drugs that are known to affect warfarin
therapy were prescribed (aspirin [61/102], statins
[22/102], and anti-diabetes drugs [17/102]), no sig-
niﬁcant differences were noted in the frequencies
among the groups compared in this research. Fur-
ther, patients were free from acute medical illness,
and renal and hepatic dysfunction.
Retrospective records
The relationship between age, PT-INR, daily dose
of warfarin, and dose/PT-INR was investigated.
From 2004 through 2005, the clinical records of
the patients at the NHO Hakodate Hospital were
obtained and were retrospectively reviewed. The
average daily warfarin dose and PT-INR were cal-
culated for each patient. Dose/PT-INR was also
calculated by dividing the mean daily dose of war-
farin by the mean PT-INR for each patient. A stable
PT-INR value was deﬁned as a value within the tar-
get range for that patient (between 1.6 and 2.6).
PT-INR was usually measured once a month.
Statistical analysesData were analyzed using SigmaStat 3.5 (Systat
Software, Inc., Richmond, CA, USA). The signiﬁ-
cance of the difference between the means of the
2 groups was assessed using the Student’s t-test
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Figure 1 The distribution of patients according to age and daily dose of warfarin. Daily dose of warfarin (mg) has
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or whom each daily dose was prescribed.
nd the Mann—Whitney rank sum test. The interre-
ationship between variables was evaluated using
earson product-moment correlation and by lin-
ar regression analysis. A non-parametric method
Spearman rank order correlation) was also used to
onﬁrm the results. p-Values <0.05 were considered
igniﬁcant.
esultshe mean age (±S.D.), the mean daily dose of
arfarin (±S.D.), the mean PT-INR (±S.D.), and
ose/PT-INR (±S.D.) of the study subjects (n = 102)
ere 70.7 (±10.5) years (range, 28—87 years),
.68 (±0.95)mg (range, 1.0—6.0mg), 1.99 (±0.24)
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Table 1 Characteristics of patients receiving warfarin the
Characteristics Age group
<50 (n = 4) 51—60 (n = 10)
Age (years) 38.8 ± 10.2 55.8 ± 2.39
Daily dose (mg) 3.20 ± 1.04 2.88 ± 1.12
PT-INR 2.02 ± 0.34 2.08 ± 0.27
Dose/PT-INR 1.72 ± 0.66 1.38 ± 0.50
Table 2 Characteristics of patients receiving warfarin the
Characteristics Age group
<65 (n = 21)
Age (years) 55.0 ± 9.7
Daily dose (mg) 3.03 ± 1.2
PT-INR 2.00 ± 0.25
Dose/PT-INR 1.54 ± 0.67tients. The regression line for the daily dose of warfarin
the right side of the bar indicate the number of patients
range, 1.60—2.59), and 1.35 (±0.50)mg (range,
.47—3.30mg), respectively.
Fig. 1 shows the daily dose of warfarin (mg)
lotted against the age (years) for each patient,
nd the regression line. The dose was signiﬁcantly
nd inversely correlated with age, as indicated
y Pearson’s correlation coefﬁcient (r) =−0.223,
= 0.00892. This correlation was conﬁrmed by using
n analysis that was independent of the distri-
ution of the data: the Spearman rank order
orrelation (R) coefﬁcient was −0.156 (p = 0.0487).
n addition, dose/PT-INR was also signiﬁcantly
nd inversely correlated with age: r =−0.202,
= 0.0153; R =−0.156, p = 0.0472 (data not shown).
n the other hand, age and PT-INR were not
orrelated: r =−0.0442, p = 0.659; R =−0.0309,
rapy according to the ﬁve age groups.
61—70 (n = 28) 71—80 (n = 44) ≥80 (n = 16)
66.4 ± 2.62 73.4 ± 1.6 82.9 ± 2.02
2.80 ± 1.19 2.65 ± 0.93 2.44 ± 0.55
2.03 ± 0.26 1.94 ± 0.22 1.95 ± 0.23
1.39 ± 0.65 1.37 ± 0.47 1.27 ± 0.34
rapy according to the 2 age groups.
p-Value
≥65 (n = 81)
74.8 ± 5.7
2.41 ± 0.87 0.236
1.99 ± 0.24 0.914
1.21 ± 0.43 0.047
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Table 3 Characteristics of patients receiving warfarin therapy according to the 2 age groups in the low PT-INR
group.
Characteristics Age group p-Value
<65 (n = 12) ≥65 (n = 53)
Age (years) 55.3 ± 11 74.7 ± 5.7
Daily dose (mg) 3.12 ± 1.2 2.60 ± 0.79 0.136
PT-INR 1.80 ± 0.13 1.85 ± 0.34 0.479
Dose/PT-INR 1.74 ± 0.57 1.41 ± 0.34 0.033
Table 4 Characteristics of patients receiving warfarin therapy according to the 2 age groups in the high PT-INR
group.
Characteristics Age group p-Value
<65 (n = 9) ≥65 (n = 28)
Age (years) 54.0 ± 8.9 75.3 ± 6.0
Daily dose (mg) 2.86 ± 1.2 2.76 ± 0.98 0.821
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IPT-INR 2.25 ± 0.15
Dose/PT-INR 1.26 ± 0.51
p = 0.758. These results suggested that aging not
only decreases the required daily dose of warfarin
but also increases the sensitivity to warfarin in
Japanese patients on optimal anticoagulant ther-
apy.
The patients were stratiﬁed into the follow-
ing 5 age groups: 50 years or younger, 51—60
years, 61—70 years, 71—80 years, and 80 years
or older (Table 1). All the groups had simi-
lar PT-INR values (approximately 2.00). On the
other hand, the daily dose and the dose/PT-
INR decreased with increased age, consistent
with the results of the above-mentioned corre-
lation analyses. It was observed that patients
in the youngest group (50 years or younger)
required a particularly higher daily dose and
showed a lower sensitivity to warfarin (higher
dose/PT-INR). Furthermore, in the remaining
groups, both the daily dose and the dose/PT-
INR when plotted against age exhibited a gentle
negative slope. The particularly higher values of
daily dose and dose/PT-INR in the youngest group
might be due to the small sample size.
To clarify whether the PT-INR affects the age-
dependent increase in warfarin sensitivity, the
patients were ﬁrst divided into 2 groups: younger
age group (<65 years, n = 21) and older age group
(≥65 years, n = 81) (Table 2). Each group was
further stratiﬁed into 2 PT-INR groups: low PT-
INR group (PT-INR≤ 2.1 low-age group, n = 12;
high-age group, n = 53); and high PT-INR group (PT-
INR > 2.1; low-age group, n = 9; high-age group,
n = 28) (Tables 3 and 4). No signiﬁcant differ-
ence was observed in the mean PT-INR between
i
w
t
t
c2.23 ± 0.15 0.887
1.23 ± 0.44 0.361
he 2 age groups within the same PT-INR groups
Tables 3 and 4).
When the 2 groups divided solely on the basis
f age were analyzed (Table 2), only the mean
ose/PT-INR was signiﬁcantly decreased in the high-
ge group; and the daily dose also appeared to be
lightly decreased. This relationship was also con-
rmed when the 2 age groups in the low PT-INR
roup were compared (Table 3). However, in the
igh PT-INR group, the differences in the daily dose
nd the dose/PT-INR between the 2 age groups were
ot statistically signiﬁcant (Table 4). Furthermore,
n comparing the 2 PT-INR groups within the same
ge groups (Tables 3 and 4), no signiﬁcant differ-
nces were noted in the mean warfarin dosages
etween the high and low PT-INR groups (low-
ge group, p = 0.140; high-age group, p = 0.360). In
ontrast, the mean dose/PT-INR signiﬁcantly dif-
ered between the 2 PT-INR groups within the same
ge group (younger age group, p = 0.011; older age
roup, p = 0.048), suggesting that most patients in
he low PT-INR group were not susceptible to war-
arin.
iscussion
nterethnic differences among patients undergo-
ng warfarin therapy involve both the sensitivity to
arfarin and the dosage required for optimal main-
enance [9,10]. The Japanese have been known
o be highly sensitive to warfarin, although the
linical evidence is limited [10]. Recently, one of
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he causes for these interethnic differences was
evealed, namely, the existence of genetic variants
f both the vitamin K epoxide reductase complex 1
ene (VKORC1) and the CYP2C9 gene. The former
ncodes the protein that is targeted by warfarin
nd functions as a limited enzyme in the vitamin
redox recycling system in the liver, while the
atter encodes a warfarin metabolizing enzyme.
hese variants are responsible for the intereth-
ic differences in the warfarin-maintenance dose
12,13].
Recently, the ‘‘Guidelines for management of
nticoagulant and antiplatelet therapy in cardio-
ascular disease’’ were established in Japan [10].
erein, it was suggested that the therapeutic range
or warfarin in the Japanese is lower than that
n Caucasians. It has been proven that at similar
T-INR values, the incidence of bleeding is higher
mong the Japanese than among the Caucasians.
oreover, a PT-INR value <1.6 does not appear to
e therapeutic [9,14]. Thus, the therapeutic range
f PT-INR among the Japanese is suggested to be
etween 1.6 and 2.6. In this study, we assessed
he subjects whose PT-INR values were controlled
ithin the target range (between 1.6 and 2.6).
We showed that both the daily dose and the
ose/PT-INR for optimal therapy show a signiﬁcant
nverse correlation with age (Fig. 1; Tables 1 and 2).
n addition, no signiﬁcant correlation was observed
etween age and PT-INR. Therefore, it is unlikely
hat the lower degree of anticoagulation in the
lderly was intentional. Thus, these analyses indi-
ated that increased age not only decreases the
equired daily dose of warfarin but also increases
he sensitivity to warfarin for the optimal manage-
ent of warfarin therapy in the Japanese.
In general, the elderly show decreased serum
roteins, metabolic activities, and excretion
hrough the kidneys [15]. These alterations lead to
ifferences in the pharmacokinetics of a drug that
ncrease the persistence of the drug in the body,
nd consequently, increased sensitivity to the drug
s observed among the elderly. However, a previous
eport has revealed that there was no apprecia-
le difference in the pharmacokinetics of warfarin,
.e. the plasma half-life, apparent volume of dis-
ribution, plasma clearance, and plasma warfarin
etabolite levels, between younger (age range,
0—40; mean, 25 years) and older (age range,
5—94; mean, 82 years) patients [16]. This suggests
hat pharmacokinetic factors did not inﬂuence the
ge-dependent increase in the sensitivity to war-
arin. One of the possibilities of the age-dependent
arfarin sensitivity is the decrease in the activity of
he vitamin K redox recycling system in the elderly
16—18].
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As mentioned in the results section, patients
ith low PT-INR values (Table 3) appeared to
e unsusceptible to warfarin therapy. Since PT-
NR values >1.6 are therapeutic for the Japanese
9,14], these dosages of warfarin were sufﬁcient
or the anticoagulant therapy. High dosages of war-
arin might induce unstable anticoagulant effects,
epending on the patients’ compliance. There-
ore, physicians may consider that in the case of
uch warfarin-unsusceptible patients, the minimum
herapeutic PT-INR should be maintained in order
o avoid prescribing a considerably high dosage of
arfarin.
Next, we focused on the PT-INR-dependent
ifference in warfarin sensitivity with increas-
ng age between the high and low PT-INR groups
Tables 3 and 4) In the high PT-INR (PT-INR > 2.1)
roup, no signiﬁcant difference was observed
etween the older and younger patients with
espect to any of the test characteristics consid-
red, while in the low PT-INR group, the mean
ose/PT-INR in the older patients was signiﬁcantly
ower than that in the younger patients (1.6≤PT-
NR≤ 2.1).
Interestingly, in spite of the difference in war-
arin sensitivity between Japanese and Caucasian
atients, a similar age-dependent difference in
he sensitivity to warfarin therapy between the
igh and low PT-INR groups was observed among
he Caucasians [3]. The investigators divided the
atients into 2 groups: the low PT-INR (2—3) and
he high PT-INR (3.1—4) groups. In the low PT-INR
roup, younger patients (65 years or less) required
median dose of 5.2mg, and older patients (more
han 65 years) required a median dose of 3.8mg
the difference was statistically signiﬁcant) [3].
n the other hand, in the high PT-INR group, no
igniﬁcant difference was observed in the median
oses of warfarin between the younger and older
atients: median doses, 5.1mg and 4.7mg, respec-
ively [3]. Thus, the age-dependent sensitivity
o warfarin therapy differed between the high
nd low PT-INR groups, regardless of the ethnic-
ty.
The above ﬁnding has not been explained from
he point of view of the age-dependent alter-
tions in pharmacokinetics [15,16] and currently,
he mechanism underlying it has not yet been
nderstood.onclusions
oth aging and the control of PT-INR values are fac-
ors responsible for the increase in the sensitivity
o warfarin in Japanese patients on optimal anti-
[[
[
[
[
[
[
[360
coagulant therapy. Since elderly Japanese patients
with low PT-INR values are especially sensitive to
warfarin, greater caution should be exercised in
determining the dosage schedule of warfarin with
increasing age in such patients.
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